Oncology Medical Minute (CME): Targeting the Tumor: Treating the Subtypes of Metastatic Breast Cancer

This article has been archived.
Please use for reference only.

Last Modified: February 3, 2012

Share article


Outcomes for women with metastatic breast cancer can be improved by the effective use of biomarkers and genomic assays to quantify individual risk and guide treatment selection. This continuing medical education activity will enhance the ability of oncologists to develop optimal treatment plans while integrating the latest clinical evidence into practice, ultimately improving outcomes in MBC.

Continue to activity


News
AACR: Lengthy Survival in Some Receiving NSCLC Vaccine

Apr 9, 2012 - Use of belagenpumatucel-L, a therapeutic vaccine comprised of four tumor growth factor-β2 antisense gene-modified allogeneic non-small-cell lung cancer (NSCLC) cell lines, is associated with encouraging long-term survival for patients with stage IIIB and IV NSCLC, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.



OncoLink Treatment Binder

Select the side effects and forms for your patient's treatment binder

Learn More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More